System and method for preventing closure of passageways

Information

  • Patent Grant
  • 7107992
  • Patent Number
    7,107,992
  • Date Filed
    Monday, October 6, 2003
    21 years ago
  • Date Issued
    Tuesday, September 19, 2006
    18 years ago
Abstract
A system for treating sleep-related breathing disorders. In one embodiment, the system includes a first magnetically susceptible material attached to a left lateral pharyngeal wall and a second magnetically susceptible material attached to a right lateral pharyngeal wall. The second magnetically susceptible material is positioned opposite the first magnetically susceptible material across an upper airway. The system further includes a first magnet disposed outside the body and lateral to the first magnetically susceptible material, and a second magnet disposed outside the body and lateral to the second magnetically susceptible material.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


Embodiments of the present invention generally relate to prevention of abnormal breathing sounds (e.g., snoring), adverse consequences, illness or death in persons due to partial or complete blockage of the upper airway.


2. Description of the Related Art


A common and potentially serious disorder in humans involves involuntary closure of the airway during sleep. This disorder is known as “sleep-disordered breathing” or “obstructive sleep apnea” (OSA). In persons with OSA, there is involuntary closure or reduction in caliber of a portion of the airway that connects the atmosphere to the lungs. The upper portion of the airway (the “upper airway”) consists of two passageways, the nasal airway and the oral airway. These two passageways merge to become a single passageway. Portions of the upper airway just behind the tongue are known as the soft palate, the pharynx, the hypopharynx, etc.


In persons affected by OSA, closure, reduction in patency or increased airflow resistance of the upper airway occurs during sleep, due to a combination of physiological changes associated with sleep (including relaxation of muscles) and the anatomy of the upper airway (which is generally smaller or more crowded than in normal individuals). In persons prone to sleep apnea, a portion or portions of the muscular walls of the upper airway may become narrow or collapse, leading to reduction in airflow (“hypopnea”), cessation of airflow (“apnea”), increase in airflow turbulence or increased resistance to airflow within the airway. In the instance of collapse, the upper airway is blocked, breathing stops, air movement to the lungs ceases, and the oxygen level in the blood tends to decrease. As a response to this process (or to less severe manifestations, such as hypopneas or increased airway resistance), a brief arousal usually occurs in the brain. As a consequence of the brief arousal, the muscle tone in the walls of the upper airway returns to waking levels, and the airway abnormality is corrected—i.e. airway resistance and patency return to normal levels.


Generally, following each event, the patient returns to sleep, until another partial or complete upper airway collapse occurs and the process repeats itself. Depending on the severity in an individual case, the number of events may range from a few per hour of sleep to more than 100 events per hour of sleep. This process disrupts normal sleep. As a consequence, patients typically suffer from the effects of sleep deprivation. Such effects may include daytime drowsiness, tiredness or fatigue, difficulties with mental concentration or memory, mood changes, reductions in performance or increases in mistakes, and increased risk of accidents. Additionally, OSA is known to increase the risk of development of other medical problems


Snoring is a mild form of sleep-disordered breathing in which increased airflow turbulence occurs. The snoring sounds result from tissue vibration within the nasal or oral airway. While snoring has been traditionally regarded as a social or cosmetic problem, recent studies suggest that snoring may be linked to the development of health problems, including high blood pressure.


Airway closure during sleep generally occurs at one or both of two levels in the upper airway: the soft palate and the hypopharynx (base of the tongue). At either level, the anterior tissue can collapse against the posterior pharyngeal wall, which makes up the rear wall of the throat. Additionally, the side (lateral) walls of the upper airway can collapse inward partially, or completely against each other. The lateral walls of the airway are susceptible to collapse in many patients with obstructive sleep apnea and other forms of sleep-related breathing disorders. In these cases, prevention of collapse of the airway only in the anterior-posterior dimension is insufficient to maintain normal airway patency. Even after extensive airway surgery for sleep apnea (which primarily addresses the anterior-posterior dimension of the airway), the patient may continue to have problems with breathing during sleep, due to lateral wall collapse or dysfunction.


Several types of treatment are available for obstructive sleep apnea and other sleep-related breathing disorders. The most common treatment consists of an air pressure delivery system that applies greater than atmospheric pressure to all walls of the upper airway to reduce the potential for full or partial collapse. Many people have difficulty using this device or prefer not to use it for various reasons. Also, surgical reconstruction of the airway or dental devices may be used. These treatments, however, often fail to treat the problem adequately.


Accordingly, a need exists in the art for an improved method and system for treating sleep apnea and other sleep-related breathing disorders.


SUMMARY OF THE INVENTION

Embodiments of the present invention are generally directed to a system for treating sleep-related breathing disorders. In one embodiment, the system includes a first magnet attached to a left lateral pharyngeal wall, and a second magnet attached to a right lateral pharyngeal wall. The second magnet is positioned opposite the first magnet across an upper airway.


In another embodiment, the system includes a first magnetically susceptible material attached to a left lateral pharyngeal wall and a second magnetically susceptible material attached to a right lateral pharyngeal wall. The second magnetically susceptible material is positioned opposite the first magnetically susceptible material across an upper airway. The system further includes a first magnet disposed outside the body and lateral to the first magnetically susceptible material, and a second magnet disposed outside the body and lateral to the second magnetically susceptible material.


In yet another embodiment, the system includes a first magnet attached to a left lateral pharyngeal wall and a second magnet attached to a right lateral pharyngeal wall. The second magnet is positioned opposite the first magnet across an upper airway. The system further includes a third magnet disposed inside the upper airway directly across from the first magnet and a fourth magnet disposed inside the upper airway directly across from the second magnet.





BRIEF DESCRIPTION OF THE DRAWINGS

The following detailed description makes reference to the accompanying drawings, which are now briefly described.



FIG. 1A, 1B, 3, 4, 5A and 5B illustrate a series of coronal views of an upper airway, each having a system for treating sleep-related breathing disorders in accordance with one embodiment of the invention.



FIG. 2 illustrates a sagittal view of the upper airway having a system for treating sleep-related breathing disorders in accordance with one embodiment of the invention.





While the invention is described herein by way of example for several embodiments and illustrative drawings, those skilled in the art will recognize that the invention is not limited to the embodiments or drawings described. It should be understood, that the drawings and detailed description thereto are not intended to limit the invention to the particular form disclosed, but on the contrary, the intention is to cover all modifications, equivalents and alternatives falling within the spirit and scope of the present invention as defined by the appended claims. The headings used herein are for organizational purposes only and are not meant to be used to limit the scope of the description or the claims. As used throughout this application, the word “may” is used in a permissive sense (i.e., meaning having the potential to), rather than the mandatory sense (i.e., meaning must). Similarly, the words “include”, “including”, and “includes” mean including, but not limited to.


DETAILED DESCRIPTION


FIG. 1A illustrates a coronal view of an upper airway 100 having a system for treating sleep apnea (and other sleep-related breathing disorders, e.g., snoring) in accordance with one embodiment of the invention. The upper airway 100 is generally defined by the anterior pharyngeal wall 110, two lateral pharyngeal walls 120, 130 and the posterior pharyngeal wall 140. The lateral pharyngeal walls 120, 130 generally include lateral pharyngeal tissue extending superiorly to the velopharynx and inferiorly to the epiglottis. The posterior pharyngeal wall 140 generally includes posterior pharyngeal tissue extending superiorly to the velopharynx and inferiorly to the epiglottis. The anterior pharyngeal wall 110 generally includes a base portion of the tongue 150, the soft palate 210 and the uvula 220 (shown in FIG. 2). Magnetically susceptible material 115 is attached to the anterior pharyngeal wall 110, magnetically susceptible material 125 is attached to the lateral pharyngeal wall 120, and magnetically susceptible material 135 is attached to the lateral pharyngeal wall 130. In one embodiment, magnetically susceptible materials 115, 125, 135 are attached to the respective pharyngeal walls by surgical sutures or bonding material, such as surgical glue. Other means for attaching the magnetically susceptible materials to the pharyngeal walls are also contemplated by embodiments of the invention described herein. In another embodiment, the magnetically susceptible materials 115, 125, 135 may be implanted inside, or embedded beneath the surface of, the respective pharyngeal walls, as shown in FIG. 1B. In yet another embodiment, the magnetically susceptible materials 115, 125, 135 may be coated on the surfaces of the respective pharyngeal walls.


The magnetically susceptible materials 115, 125, 135 may be materials, which are not magnets, but are susceptible to magnetic fields, such as ferromagnetic materials. As such, magnetically susceptible materials 115, 125, 135 would not interact with each other in the absence of a magnetic field, such as, during daytime, as opposed to permanent magnets that would potentially interact with each other at all times, which may be inappropriate or even deleterious (e.g., during speaking or swallowing) to a person's health. Magnetically susceptible materials 115, 125, 135 may be in the form of plates, discs, spheres, bars, multiple small pieces, mesh and the like. In an alternate embodiment, the magnetically susceptible materials 115, 125, 135 may be replaced with magnets, such as permanent magnets with magnetic fields of fixed strength or variable magnets (e.g., electromagnets) with magnetic fields of variable strength (including zero if not activated).


Magnet 160 is positioned outside the body and lateral to magnetically susceptible material 125, while magnet 170 is positioned outside the body and lateral to magnetically susceptible material 135, and magnet 180 is positioned outside the body and anterior to magnetically susceptible material 115. Magnets 160, 170, 180 may be attached or placed adjacent to the outer skin 151 of a patient with means, such as a neckband or a chin strap. In one embodiment, magnets 160, 170, 180 may be implanted beneath the outer skin surface, such as, beneath the front skin 211 of the cheek 266 for magnet 160, as shown in FIG. 2.


Magnet 160 is configured to attract magnetically susceptible material 125 toward magnet 160 so that movement of the lateral pharyngeal wall 120 toward closure of the upper airway 100 may be opposed. Magnet 170 is configured to attract magnetically susceptible material 135 toward magnet 170 so that movement of the lateral pharyngeal wall 130 toward closure of the upper airway 100 may be opposed. Magnet 180 is configured to attract magnetically susceptible material 115 toward magnet 180 so that movement of the anterior pharyngeal wall 110 toward closure of the upper airway 100 may be opposed. In this manner, the cross sectional dimensions (e.g., the length or width) of the upper airway 100 may be increased or prevented from decreasing, thereby allowing patency of the upper airway 100 to be maintained.


Force fields between magnet 160 and magnetically susceptible material 125 and between magnet 170 and magnetically susceptible material 135 act to keep the soft tissue of the lateral pharyngeal walls 120, 130 from collapsing. Force fields between magnet 180 and magnetically susceptible material 115 act to keep the soft tissue of the anterior pharyngeal wall 110 from collapsing toward the posterior pharyngeal wall 140.



FIG. 3 illustrates a coronal view of an upper airway 300 having a system 350 for treating sleep apnea (and other sleep-related breathing disorders, e.g., snoring) in accordance with another embodiment of the invention. The system 350 includes magnet 315 attached to an anterior pharyngeal wall 310, magnet 325 attached to lateral pharyngeal wall 320, magnet 335 attached to lateral pharyngeal wall 330, and magnet 345 attached to posterior pharyngeal wall 340. In one embodiment, magnets 315, 325, 335, 345 are attached to the respective pharyngeal walls by surgical sutures or bonding material, such as surgical glue. Other means for attaching the magnets to the pharyngeal walls are also contemplated by embodiments of the invention described herein. In another embodiment, magnets 315, 325, 335, 345 may be implanted inside (e.g., embedded beneath the surface of) the respective pharyngeal walls. In yet another embodiment, magnets 315, 325, 335, 345 may be coated on surfaces of the respective pharyngeal walls.


Magnets 315, 325, 335, 345 may be permanent magnets with magnetic fields of fixed strength or variable magnets, such as electro-magnets, with magnetic fields of variable strength (including zero if not activated).


Magnets 315, 325, 335, 345 are oriented such that the same magnetic poles of the magnets 315, 325, 335, 345 face each other, e.g., north poles facing other north poles. In operation, magnets 315, 325, 335, 345 are configured to repel each other, thereby opposing closure of the upper airway 300 without the use of external magnets.



FIG. 4 illustrates a coronal view of an upper airway 400 having a system 450 for treating sleep apnea (and other sleep-related breathing disorders, e.g., snoring) in accordance with yet another embodiment of the invention. The system 450 includes magnet 425 attached to lateral pharyngeal wall 420 and magnet 435 attached to lateral pharyngeal wall 430. In one embodiment, magnets 425, 435 are attached to the respective lateral pharyngeal walls by surgical sutures or bonding material, such as surgical glue. Other means for attaching the magnets to the lateral pharyngeal walls are also contemplated by embodiments of the invention described herein. In another embodiment, magnets 425, 435 may be implanted inside (e.g., embedded beneath the surface of) the respective lateral pharyngeal walls. In yet another embodiment, magnets 425, 435 may be coated on surfaces of the respective lateral pharyngeal walls.


Magnets 425, 435 may be permanent magnets with magnetic fields of fixed strength or variable magnets, such as electromagnets, with magnetic fields of variable strength (including zero if not activated). Magnets 425, 435 are oriented such that the same magnetic poles of the magnets 425, 435 face each other, e.g., north pole facing other north pole. In operation, magnets 425, 435 are configured to repel each other, thereby opposing closure of the upper airway 400 without the use of external magnets.



FIGS. 5A and 5B illustrates a system 550 for treating sleep apnea (and other sleep-related breathing disorders, e.g. snoring) disposed inside an upper airway 500 in accordance with still another embodiment of the invention. The system 550 includes magnet 525 attached to lateral pharyngeal wall 530. In one embodiment shown in FIG. 5B, magnets 525, 535 may be attached to the lateral pharyngeal walls 520, 530, by surgical sutures or bonding material 580, such as surgical glue. Other means for attaching the magnets to the pharyngeal walls are also contemplated by embodiments of the invention described herein. In another embodiment, magnets 525, 535 may be implanted inside the lateral pharyngeal walls 520, 530. In yet another embodiment, magnets 525, 535 may be coated on surfaces of the lateral pharyngeal walls 520, 530. Magnets 525, 535 may be permanent magnets with magnetic fields of fixed strength or variable magnets, such as electro-magnets, with magnetic fields of variable strength (including zero if not activated).


The system 550 further includes magnets 560 and 570 disposed inside the upper airway 500. Magnet 560 is disposed across from magnet 525, while magnet 570 is disposed across from magnet 535. The magnetic poles of magnets 560, 570 are oriented such that magnets 560, 570 repel magnets 525, 535, respectively, thereby opposing closure of the upper airway 500 without the use of external magnets. Magnets 560, 570 may be attached to or held in place by a removable apparatus 580, such as a mouthpiece.


Each magnet or magnetically susceptible material described herein may comprise more than one magnet or magnetically susceptible material. Although embodiments of the invention have been described with reference to two or four magnetically susceptible materials or magnets, embodiments of the invention also contemplate other combinations or numbers of magnets and magnetically susceptible materials. Although embodiments of the invention have been described with reference to treating sleep-related breathing disorders, such as sleep apnea or snoring, embodiments of the invention also contemplate other applications where passageway or airway patency is required. For example, the magnets or magnetically susceptible materials may be inserted or attached through a body aperture, such as the vagina, the rectum, the urinary passage and the like.


While the foregoing is directed to embodiments of the present invention, other and further embodiments of the invention may be devised without departing from the basic scope thereof, and the scope thereof is determined by the claims that follow.

Claims
  • 1. A system for preventing sleep apnea and other sleep-related breathing disorders, comprising: a first magnet attached to a left lateral pharyngeal wall; a second magnet attached to a right lateral pharyngeal wall, wherein the second magnet is positioned opposite the first magnet across an upper airway; a third magnet disposed inside the upper airway directly across from the first magnet; and a fourth magnet disposed inside the upper airway directly across from the second magnet.
  • 2. The system of claim 1, wherein the third magnet generates a magnetic field that repels the first magnet away from the third magnet, and wherein the fourth magnet generates a magnetic field that repels the second magnet away from the fourth magnet.
  • 3. The system of claim 1, wherein the third and fourth magnets are attached to a removable apparatus to hold the third and fourth magnets inside the upper airway.
  • 4. The system of claim 1, wherein the first and the second magnet are attached to the left and right lateral pharyngeal walls by surgical sutures or bonding material.
  • 5. The system of claim 1, wherein the first and second magnets are one of permanent and variable magnets.
  • 6. A method for treating sleep-related breathing disorders, comprising: attaching a first magnet to a left lateral pharyngeal wall; attaching a second magnet to a right lateral pharyngeal wall opposite the first magnet across an upper airway; disposing a third magnet inside the upper airway directly across from the first magnet; and disposing a fourth magnet inside the upper airway directly across from the second magnet.
  • 7. The method of claim 6, further comprising: repelling the first magnet away from the third magnet; and repelling the second magnet away from the fourth magnet.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims benefit of U.S. provisional patent application Ser. No. 60/415,995, filed Oct. 4, 2002, which is herein incorporated by reference.

US Referenced Citations (102)
Number Name Date Kind
4978323 Freedman Dec 1990 A
5015538 Krause et al. May 1991 A
5117816 Shapiro et al. Jun 1992 A
5176618 Freedman Jan 1993 A
5199424 Sullivan et al. Apr 1993 A
5245995 Sullivan et al. Sep 1993 A
5268082 Oguro et al. Dec 1993 A
5284161 Karell Feb 1994 A
5479944 Petruson Jan 1996 A
5509888 Miller Apr 1996 A
5522382 Sullivan et al. Jun 1996 A
5551418 Estes et al. Sep 1996 A
5823187 Estes et al. Oct 1998 A
5873363 Esmailzadeh Feb 1999 A
RE36120 Karell Mar 1999 E
5901704 Estes et al. May 1999 A
5904141 Estes et al. May 1999 A
5970975 Estes et al. Oct 1999 A
5980998 Sharma et al. Nov 1999 A
5988171 Sohn et al. Nov 1999 A
6092523 Belfer Jul 2000 A
6098629 Johnson et al. Aug 2000 A
6109852 Shahinpoor et al. Aug 2000 A
6190893 Shastri et al. Feb 2001 B1
6212435 Lattner et al. Apr 2001 B1
6250307 Conrad et al. Jun 2001 B1
6257234 Sun Jul 2001 B1
6376971 Pelrine et al. Apr 2002 B1
6379393 Mavroidis et al. Apr 2002 B1
6390096 Conrad et al. May 2002 B1
6401717 Conrad et al. Jun 2002 B1
6408851 Karell Jun 2002 B1
6415796 Conrad et al. Jul 2002 B1
6431174 Knudson et al. Aug 2002 B1
6439238 Brenzel et al. Aug 2002 B1
6450169 Conrad et al. Sep 2002 B1
6453905 Conrad et al. Sep 2002 B1
6454803 Romo, III Sep 2002 B1
6467485 Schmidt Oct 2002 B1
6475639 Shahinpoor et al. Nov 2002 B1
6502574 Stevens et al. Jan 2003 B1
6513530 Knudson et al. Feb 2003 B1
6513531 Knudson et al. Feb 2003 B1
6514237 Maseda Feb 2003 B1
6516806 Knudson et al. Feb 2003 B1
6523541 Knudson et al. Feb 2003 B1
6523542 Knudson et al. Feb 2003 B1
6523543 Conrad et al. Feb 2003 B1
6529777 Holmstrom et al. Mar 2003 B1
6545384 Pelrine et al. Apr 2003 B1
6546936 Knudson et al. Apr 2003 B1
6569654 Shastri et al. May 2003 B1
6578580 Conrad et al. Jun 2003 B1
6583533 Pelrine et al. Jun 2003 B1
6586859 Kornbluh et al. Jul 2003 B1
6601584 Knudson et al. Aug 2003 B1
6601585 Conrad et al. Aug 2003 B1
6618627 Lattner et al. Sep 2003 B1
6619290 Zacco Sep 2003 B1
6626181 Knudson et al. Sep 2003 B1
6628040 Pelrine et al. Sep 2003 B1
6629527 Estes et al. Oct 2003 B1
6634362 Conrad et al. Oct 2003 B1
6636767 Knudson et al. Oct 2003 B1
6664718 Pelrine et al. Dec 2003 B1
6667825 Lu et al. Dec 2003 B1
6679836 Couvillon, Jr. Jan 2004 B1
6707236 Pelrine et al. Mar 2004 B1
6742524 Knudson et al. Jun 2004 B1
6748951 Schmidt Jun 2004 B1
6749556 Banik Jun 2004 B1
6768246 Pelrine et al. Jul 2004 B1
6770027 Banik et al. Aug 2004 B1
6781284 Pelrine et al. Aug 2004 B1
6812624 Pei et al. Nov 2004 B1
6835173 Couvillon, Jr. Dec 2004 B1
6955172 Nelson et al. Oct 2005 B1
20020173848 Sachs Nov 2002 A1
20030015198 Hecke et al. Jan 2003 A1
20030140930 Knudson et al. Jul 2003 A1
20030149445 Knudson et al. Aug 2003 A1
20030149488 Metzger et al. Aug 2003 A1
20030192556 Conrad et al. Oct 2003 A1
20030196669 Conrad et al. Oct 2003 A1
20040016433 Estes et al. Jan 2004 A1
20040019368 Lattner et al. Jan 2004 A1
20040020497 Knudson et al. Feb 2004 A1
20040020498 Knudson et al. Feb 2004 A1
20040045555 Nelson et al. Mar 2004 A1
20040045556 Nelson et al. Mar 2004 A1
20040073272 Knudson et al. Apr 2004 A1
20040134491 Pflueger et al. Jul 2004 A1
20040139975 Nelson et al. Jul 2004 A1
20040149290 Nelson et al. Aug 2004 A1
20040172054 Metzger et al. Sep 2004 A1
20050004417 Nelson et al. Jan 2005 A1
20050115572 Brooks et al. Jun 2005 A1
20050121039 Brooks et al. Jun 2005 A1
20050159637 Nelson et al. Jul 2005 A9
20050199248 Pflueger et al. Sep 2005 A1
20050268919 Knudson et al. Dec 2005 A1
20050284485 Nelson et al. Dec 2005 A9
Foreign Referenced Citations (17)
Number Date Country
4412190 Oct 1995 DE
0312368 Apr 1989 EP
0743076 Nov 1996 EP
1306104 May 2003 EP
WO 8810108 Dec 1988 WO
WO 9611653 Apr 1996 WO
WO 9726039 Jul 1997 WO
WO 0119301 Mar 2001 WO
WO 0213738 Feb 2002 WO
WO 02056876 Jul 2002 WO
WO 02076341 Oct 2002 WO
WO 02076352 Oct 2002 WO
WO 02076353 Oct 2002 WO
WO 02076354 Oct 2002 WO
WO 03041612 May 2003 WO
WO 03065947 Aug 2003 WO
WO 2004043288 May 2004 WO
Related Publications (1)
Number Date Country
20040112390 A1 Jun 2004 US
Provisional Applications (1)
Number Date Country
60415995 Oct 2002 US